The global market for Antisense and RNAi Therapeutics estimated at US$ 1.2 Billion in the year 2020, is projected to reach a revised size of US$ 1.9 Billion by 2027, growing at a CAGR of 6% over the period 2021-2027.
Antisense and RNAi therapeutics are a new class of drugs that work by silencing parts of RNA through the use of short interfering RNAs (siRNAs) or microRNAs (miRNAs) that cause disease or induce degradation of target mRNAs. Reduce the translation of undesirable proteins using RNases.
(Get 15% Discount on Buying this Report)
A full report of Global Antisense and RNAi Therapeutics Market is available at: https://www.orionmarketreports.com/antisense-and-rnai-therapeutics-market/56620/
Market Segments
By Technology
• RNA Interference
• Antisense RNA
By Application
• Oncology
• Cardiovascular Diseases (CVDs)
• Respiratory Disorders
• Renal Diseases
• Neurodegenerative Disorders
• Genetic Disorders
• Infectious Diseases
• Other
By Route of Administration
• Pulmonary Delivery
• Intravenous Injections
• Intra-dermal Injections
• Intraperitoneal Injections
• Topical Delivery
• Other
Key Players
Some of the industry players in this market include Alnylam, Mirus Bio, Marina Biotech, Benitec Biopharma, RXi pharmaceuticals, Qiagen, Genzyme, and Moderna.
Scope of the Report
The research study analyzes the global Antisense and RNAi Therapeutics industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:
Recent Developments
o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment
Geographic Coverage
o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume
Key Questions Answered by Antisense and RNAi Therapeutics Market Report
1. What was the Antisense and RNAi Therapeutics Market size in 2019 and 2020; what are the estimated growth trends and market forecast (2021-2027).
2. What will be the CAGR of the Antisense and RNAi Therapeutics Market during the forecast period (2021-2027)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2021? How these segments are expected to grow during the forecast period (2021-2027).
4. Which manufacturer/vendor/players in the Antisense and RNAi Therapeutics Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.
The report covers the following objectives:
- Proliferation and maturation of trade in the global Antisense and RNAi Therapeutics market.
- The market share of the global Antisense and RNAi Therapeutics market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
- Current and future market trends that are influencing the growth opportunities and growth rate of the global Antisense and RNAi Therapeutics market.
- Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Antisense and RNAi Therapeutics market.
About Us:
Orion Market Reports (OMR) endeavors to provide an exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and the most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
